Clone:
REAL335
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC
Alternative names:
Tetraspanin-26 (Tspan-26, TSPAN26)

Extended validation for CD37 Antibody, anti-human,
REAlease
®

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REAL335
M-B371++
MB-1++
REA366++
Cells were incubated with an excess of purified unconjugated CD37 (REAL335) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD37. Human peripheral blood mononuclear cells (PBMCs) were stained with CD37 antibodies and with a suitable counterstaining. As a control, CD37 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD37. Human peripheral blood mononuclear cells (PBMCs) were stained with CD37 antibodies and with a suitable counterstaining. As a control, CD37 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD37. Human peripheral blood mononuclear cells (PBMCs) were stained with CD37 antibodies and with a suitable counterstaining. As a control, CD37 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD37. Human peripheral blood mononuclear cells (PBMCs) were stained with CD37 antibodies and with a suitable counterstaining. As a control, CD37 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD37. Human peripheral blood mononuclear cells (PBMCs) were stained with CD37 antibodies and with a suitable counterstaining. As a control, CD37 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD37 (REAL335). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD37 (REAL335). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD37 (REAL335). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD37 Antibody, anti-human,
REAlease
®

Overview

Clone REAL335 is an antibody fragment derived from the full CD37 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL335 recognizes the human CD37 antigen, a multi-pass membrane protein which is also known as tetraspanin-26 (Tspan-26). CD37 is a member of the transmembrane 4 superfamily of tetraspanin proteins, which consist of four potential membrane-spanning regions, two extracellular loops, and two short intracytoplasmic tails. Although most tetraspanins are ubiquitous proteins, CD37 expression is nearly exclusively limited to mature B cells and B cell–derived lymphoid malignancies. B cell early progenitors, T cells, natural killer cells, and myeloid cells exhibit only minimal amounts of membrane-associated CD37. In innate immunity, CD37 interacts with pattern recognition receptor Dectin-1, stabilizing Dectin-1 at the macrophage cell surface, and negatively regulating proinflammatory cytokine secretion following ligand recognition. Adaptive humoral immune responses are also perturbed by CD37 ablation. In cellular immunity, CD37 negatively regulates T cell proliferation. In antigen-presenting cells, CD37 associates with MHC class II at the cell surface and has been shown to negatively regulate antigen presentation. CD37 has recently attracted interest as a target for monoclonal antibodies with therapeutic potential in B cell malignancies.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

Tetraspanin-26 (Tspan-26, TSPAN26)

Detailed product information

Technical specifications

CloneREAL335
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD37
Alternative names of antigenTetraspanin-26 (Tspan-26, TSPAN26)
Distribution of antigenB cells, T cells, NK cells, myeloid cells
RRIDAB_2751688, AB_2784169, AB_2784168, AB_2784170, AB_2811695, AB_2751709

Resources for CD37 Antibody, anti-human,
REAlease
®

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

Related products for
CD37 Antibody, anti-human,
REAlease
®

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?